Tirzepatide vs semaglutide head-to-head: SURMOUNT-5 explained
For years the tirzepatide-vs-semaglutide debate relied on comparing separate trials. SURMOUNT-5 finally pitted them directly against each other. Here's what it found and what it means for your choice.
What the trial found
SURMOUNT-5 was a direct, randomized comparison of maximum-tolerated tirzepatide versus maximum-tolerated semaglutide in adults with obesity. Over 72 weeks, tirzepatide delivered about 20.2% weight loss to semaglutide's 13.7% — a roughly 6.5-percentage-point advantage.
This confirmed what cross-trial comparisons had suggested: tirzepatide's dual GIP/GLP-1 mechanism produces more weight loss on average than semaglutide's GLP-1-only action.
A head-to-head design matters because it removes the confounders that plague cross-trial comparisons — different populations, time periods, and protocols. When the same trial randomizes patients to both drugs under identical conditions, the difference it measures is far more trustworthy.
Why tirzepatide wins on weight
Tirzepatide activates two gut-hormone receptors — GIP and GLP-1 — while semaglutide activates only GLP-1. The dual action appears to produce greater appetite suppression and metabolic effect, translating into more weight loss.
That mechanistic edge shows up consistently: tirzepatide's SURMOUNT-1 (~20.9%) exceeds semaglutide's STEP 1 (~14.9%), and the head-to-head confirms it directly.
Mechanism isn't everything, though. The dual action may also explain tirzepatide's slightly different side-effect profile and its unique approval for obstructive sleep apnea — so the two drugs aren't just weaker and stronger versions of the same thing, but genuinely different tools.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Head-to-head weight loss | 20.2% | 13.7% |
| Mechanism | GIP + GLP-1 | GLP-1 only |
| CV outcome data | Emerging | SELECT (20% MACE↓) |
| Sleep apnea approval | Yes (SURMOUNT-OSA) | No |
| Typical cash-pay cost | Higher | Lower |
Who should choose which
Choose tirzepatide if maximum weight loss is the priority and cost is manageable. Choose semaglutide if cardiovascular risk reduction is a primary goal (it has the landmark SELECT outcome data), if cost is a bigger constraint, or if you tolerate it better.
Neither is a bad choice — both dramatically outperform older weight-loss drugs. The head-to-head simply gives tirzepatide the edge on the specific outcome of weight loss.
It's also reasonable to start on one and switch. Some patients begin on semaglutide for cost or coverage reasons and move to tirzepatide if they plateau short of their goal; others do the reverse for tolerability. The molecules aren't a lifetime commitment.
The bottom line
SURMOUNT-5 settled the weight-loss question: tirzepatide produces more, at 20.2% versus 13.7% head-to-head. But 'more weight loss' isn't the only axis — semaglutide's cardiovascular evidence and lower cost keep it the better pick for many patients.
Treat the decision as a match between the drug's strengths and your priorities, not a search for a single 'best.' If you want maximum loss and can manage the cost, tirzepatide leads; if cardiovascular protection or affordability ranks higher, semaglutide is a strong, evidence-backed choice.
Across the trials, the biggest results belonged to patients who treated tirzepatide as one part of a durable routine — effective dose reached and held, protein and resistance training in place, and follow-up maintained. Because the benefits depend on continuation, the sustainability of your program (its cost, support, and convenience) is as decisive as the medication itself.
How we verify pricing & evidence
The prices here come from the RangeYourself independent telehealth price index, human-verified against each provider's public pricing page during July 1–3, 2026 (CC-BY-4.0, attributed). Efficacy and safety figures are drawn from the STEP (semaglutide) and SURMOUNT (tirzepatide) pivotal-trial programs and peer-reviewed outcome studies. Prices change, so confirm the current rate at your dose before deciding — and note that compounded GLP-1s are not FDA-approved and aren't identical to the brand drugs studied in those trials.
Frequently asked questions
For weight loss, tirzepatide — SURMOUNT-5 head-to-head showed 20.2% vs 13.7%. Semaglutide leads on cardiovascular outcome evidence, so 'more effective' depends on the goal.
A randomized head-to-head trial directly comparing maximum-tolerated tirzepatide and semaglutide in adults with obesity over 72 weeks. Tirzepatide produced significantly more weight loss.
It activates two receptors (GIP and GLP-1) versus semaglutide's one (GLP-1), producing greater appetite suppression and metabolic effect on average.
Yes, under clinician guidance. Some patients switch from semaglutide to tirzepatide after plateauing, or the reverse for tolerability or cost reasons.
Key takeaways
- SURMOUNT-5 head-to-head: tirzepatide ~20.2% vs semaglutide ~13.7% over 72 weeks.
- Tirzepatide's dual GIP/GLP-1 mechanism drives the larger weight loss.
- Semaglutide leads on cardiovascular outcome evidence (SELECT, 20% MACE reduction).
- Tirzepatide is uniquely approved for obstructive sleep apnea (SURMOUNT-OSA).